ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
61.10
+0.15 (+0.25%)
At close: 4:00PM EDT

61.10 0.00 (0.00%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close60.95
Open60.75
Bid59.95 x 1400
Ask61.90 x 1000
Day's Range60.40 - 62.00
52 Week Range10.05 - 62.75
Volume513,328
Avg. Volume694,114
Market Cap2.152B
Beta1.93
PE Ratio (TTM)N/A
EPS (TTM)-4.56
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.20
Trade prices are not sourced from all markets
  • ACCESSWIRE14 hours ago

    Free Pre-Market Technical Recap on TherapeuticsMD and Three Additional Healthcare Stocks

    LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX).

  • Zogenix (ZGNX) in Focus: Stock Moves 9.8% Higher
    Zacks2 days ago

    Zogenix (ZGNX) in Focus: Stock Moves 9.8% Higher

    Zogenix (ZGNX) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: Zogenix and Momenta Pharmaceuticals

    While the Dow reclaimed its above 25,000 levels after almost a month Nasdaq is at a record high. The Dow Jones Industrial Average gained 0.38 percent to close at 25,019.41, while the S&P 500 Index increased 0.11 percent to close at 2,801.31. The Nasdaq Composite Index climbed 0.03 percent to close at 7,825.98.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool3 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot biotech stocks get even hotter?

  • Why Zogenix Inc. Shares Jumped 10% on Friday
    Motley Fool4 days ago

    Why Zogenix Inc. Shares Jumped 10% on Friday

    Wall Street is cheering the latest data for the company's epilepsy drug.

  • Zogenix's Epilepsy Candidate Successful in Phase III Study
    Zacks5 days ago

    Zogenix's Epilepsy Candidate Successful in Phase III Study

    Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.

  • Benzinga5 days ago

    Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...

  • ACCESSWIRE5 days ago

    Today's Research Reports on Stocks to Watch: Galmed Pharmaceuticals and Zogenix

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / An analyst at Cantor Fitzgerald thinking that Galmed Pharmaceuticals is undervalued in the NASH space had traders cheering on Thursday, sending shares higher ...

  • Why Twitter, Papa John's International, and Zogenix Jumped Today
    Motley Fool5 days ago

    Why Twitter, Papa John's International, and Zogenix Jumped Today

    The market cheered after one of these companies distanced itself from its founder.

  • Zogenix Stock Soars on Positive Clinical Trial Results
    Market Realist5 days ago

    Zogenix Stock Soars on Positive Clinical Trial Results

    Today, Zogenix stock is trading at $55.72, which represents a ~20.35% rise from yesterday’s close of $46.30. Zogenix also hit a 52-week high of $58.30 today, and yesterday’s closing price was ~361% higher than its 52-week low of $10.05 on August 11, 2017.

  • Zogenix (ZGNX) Stock Soars on Anti-Seizure Drug Results
    InvestorPlace5 days ago

    Zogenix (ZGNX) Stock Soars on Anti-Seizure Drug Results

    Zogenix (NASDAQ:ZGNX) shares were soaring on Thursday following the results of the company’s anti-seizure drug, which has proven to be effective in its latest clinical trial. The drugmaker developed a drug designed to treat a rare form of childhood epilepsy and it has reportedly been effective in reducing convulsive seizures in a second late-stage trial, with the company’s stock soaring as much as 26% earlier in the day thanks to these results. The move from Zogenix means that the drug is one step closer to coming to the market to treat Dravet syndrome. The ailment affects an estimated 20,000 patients in the U.S. but current treatments only include a combination of seizure medication and drugs to prevent emergencies.

  • Why Zogenix Inc. Is Soaring Today
    Motley Fool5 days ago

    Why Zogenix Inc. Is Soaring Today

    Traders cheer after the company reports positive clinical results. Here's what investors need to know.

  • Reuters5 days ago

    Zogenix's seizure drug clears late-stage trial, shares soar

    Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent. The successful trial takes the company one step closer to bringing the drug to the market, and comes close on the heels of regulatory approval for GW Pharmaceuticals Plc's cannabis-based treatment for the same form of epilepsy. Current treatment options for Dravet syndrome, which affects an estimated 20,000 patients in the United States, are limited to a combination of seizure medication and drugs to prevent emergencies.

  • MarketWatch6 days ago

    Zogenix shares soar 19% premarket after news of positive trial for severe epilepsy treatment

    The company said the Phase 3 study of its investigational drug ZX008 met its primary endpoint of reducing convulsive seizure frequency, as well as secondary endpoints. "These impressive study results show the significant impact the addition of ZX008 made in reducing the burden of convulsive seizures for patients who are not adequately controlled using stiripentol, the standard of care for the treatment of Dravet syndrome in Europe," said Professor Rima Nabbout, M.D., Ph.D., Department of Pediatric Neurology, Reference Center for Rare Epilepsies, Necker Enfants Malades Hospital, and Principal Investigator of the trial, called Study 1504.

  • Reuters6 days ago

    Zogenix's treatment for rare epilepsy meets advanced study goal

    Zogenix Inc said on Thursday its drug to treat Dravet syndrome, a rare form of epilepsy, met the main goal of a late-stage trial. The study, the second late-stage trial of the drug, found that the treatment ...

  • GlobeNewswire6 days ago

    Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

    Primary Endpoint Achieved- Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures. ZX008 Also Demonstrated Statistical Significance in All ...

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool14 days ago

    3 Biotech Stocks With Major Catalysts Incoming

    The third quarter of 2018 will be awfully exciting for owners of these three stocks.

  • GlobeNewswire15 days ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    The awards were made on July 2, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. Mr. Sagrolikar was granted inducement awards consisting of options to purchase 100,000 shares of Zogenix common stock and 15,000 restricted stock units.

  • GlobeNewswire16 days ago

    Zogenix Welcomes New Global Chief Commercial Officer

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Ashish Sagrolikar has joined the Company as Executive Vice President and Chief Commercial Officer. Mr. Sagrolikar has over 25 years of global pharmaceutical sales, marketing and operations experience. Prior to joining Zogenix, he spent the last 16 years leading commercial strategies for rare disease and specialty pharmaceutical products, most recently at GlaxoSmithKline (GSK) and Baxter International.

  • InvestorPlace20 days ago

    Here’s the Reason that GWPH Stock Tumbled Despite Regulatory Victory

    At first glance, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is one of those investments that should be moving higher, but it GWPH stock isn’t. Analysts recognize the pharmaceutical company for its alternative therapies, specifically involving cannabidiol (CBD). Just recently, regulatory officials granted their CBD-based, anti-seizure drug Epidiolex the green light.

  • Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?
    Zacks29 days ago

    Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?

    Investors in Zogenix (ZGNX) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRElast month

    Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks

    Stock Research Monitor: ZGNX, DEPO, and DRRX LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ENDP sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • GlobeNewswire2 months ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    The awards were made on June 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 28,200 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $42.50, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • This Cannabis-Based Drug Is On the Verge of Making History
    Motley Fool2 months ago

    This Cannabis-Based Drug Is On the Verge of Making History

    If approved by the FDA, this cannabidiol-based drug may have an opportunity to (partially) reform federal law.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ZGNX earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 Zogenix Inc Earnings Call